Atropine

CHEMBL517712 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
289.4 g/mol
LogP
1.8
Phase
4

A muscarinic receptor antagonist derived from the belladonna plant that blocks the effects of acetylcholine on the parasympathetic nervous system, increasing heart rate, drying secretions, and relaxing smooth muscle. It is used in emergencies for bradycardia and to reverse certain poisonings.

Peso Molecular

289,4000 g/mol

LogP

1,80

TPSA

49,80 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2

InChI

InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?

Molecular Formula

C17H23NO3

HBD / HBA

1 / 4

Ligações Rotacionáveis

5

Átomos Pesados

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A muscarinic receptor antagonist derived from the belladonna plant that blocks the effects of acetylcholine on the parasympathetic nervous system, increasing heart rate, drying secretions, and relaxing smooth muscle. It is used in emergencies for bradycardia and to reverse certain poisonings.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Atropine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL517712. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 174174. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.